Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Korea Otsuka Pharmaceutical Co., Ltd.
Age
19–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patients with schizophrenia or bipolar 1 disorder
Patients who are prescribed Abilify Maintena® Injections treatment as per investigator's medical judgment
Patients giving written authorization to use their personal and health data and starting Abilify Maintena® Injections treatment after agreement is in place and investigators provide the explanation about objective and feature of the surveillance
You may not be if
Patients with known hypersensitivity to Aripiprazole or any excipients of Abilify Maintena® Injections
Elderly patients with dementia related psychosis
Patients who have been treated with Abilify Maintena® Injections
Patients with score 0(Not assessed) or 1(Normal, not at all ill) in the Clinical Global Impression-Severity(CGI-S)
Patients participating in other clinical trial
Clareo Health | Abilify Maintena PMS in Schizophrenia Patients or Bipolar 1 Disorder
